Navigation Links
Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif(R) at 16 Weeks in Patients With Multiple Sclerosis
Date:9/21/2008

ts treated with the new formulation of Rebif(R) had zero combined unique active brain lesions at week 16, compared to only 16.7% in the placebo group.

Results for the secondary and tertiary endpoints of the IMPROVE study will be available at the end of the 40-week treatment period.

The safety profile of the new formulation of Rebif(R) reported in this study is consistent with the known safety profile of Rebif(R). No unexpected safety concerns were identified in this study.

The new formulation of Rebif(R) was approved in the European Union in August 2007 and in Canada in September 2007. It is now marketed in all EU countries and in Canada. The new formulation of Rebif(R) is not available in the United States.

About Rebif(R)

Rebif(R) (interferon beta-1a) is a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS) and is similar to the interferon beta protein produced by the human body. The efficacy of Rebif(R) in chronic progressive MS has not been established. Interferons are thought to help modulate the body's immune system and reduce inflammation. The exact mechanism is unknown.

Rebif(R), which was approved in Europe in 1998 and in the US in 2002, is registered in more than 80 countries worldwide. Rebif(R) has been proven to delay the progression of disability, reduce the frequency of relapses and reduce MRI lesion activity and area.* Rebif(R) is available in a 22 micrograms and 44 micrograms ready-to-use pre-filled syringe and a titration pack (8.8 micrograms).

Rebif(R) should be used with caution in patients with a history of depression, liver disease and seizures. Most commonly reported side effects are flu-like symptoms, injection site disorders, elevation of liver enzymes and blood cell abnormalities. Patients, especially those with depression, seizure disorders, or liver problems, should discuss treatment with Rebif(R) with their doctors. For more information about Rebif(R), please visi
'/>"/>

SOURCE Merck Serono
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Haemacure Reports Third Quarter 2007 Results
2. Brooke Franchise Corporation Announces Selected July Results
3. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
4. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
5. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
6. NBTY Announces Preliminary Unaudited Net Sales Results For August 2007
7. Martek Announces Third Quarter 2007 Financial Results
8. MDS Reports Third Quarter 2007 Results
9. Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007
10. Robbins & Myers to Release Fourth Quarter and 2007 Fiscal Year Results on Monday, October 15, 2007
11. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... compound that targets an important brain receptor has a ... including relapse behavior, a University at Buffalo animal study ... this may be a novel lead compound for treating ... UB research was published as an online preview article ... study, the compound, RO5263397, severely blunted a broad range ...
(Date:4/23/2014)... methods that can rapidly screen a large cell ... inside that population has been seriously lacking," said ... the Royal Society of Chemistry journal Chemical ... his coworkers have developed a novel technique that ... Chem. Sci. , 2014, DOI: 10.1039/C4SC00578C, http://pubs.rsc.org/en/content/articlelanding/2014/sc/c4sc00578c#!divAbstract ...
(Date:4/23/2014)... as the United States, it may come as a surprise ... adequate food due to lack of money or other financial ... the University of Illinois using data from the National Health ... are dealing with hunger are also facing negative health and ... over age 60 faced the threat of hungerthat translates to ...
(Date:4/23/2014)... of Midlife Occupational and Leisure Time Physical Activity on ... activity in midlife increases the risk of mobility limitation ... risk. This is found in a study which followed ... study was conducted at the Gerontology Research Center in ... Heavy physical labor is often repetitive, wears the body ...
(Date:4/23/2014)... has been a rapidly evolving pursuit with many ... in the research road, scientists have found a ... with the disease. The report, which appears in ... have important implications for developing novel treatments. , ... that for years, research has suggested a link ...
Breaking Medicine News(10 mins):Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:More Americans in their golden years are going hungry 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2
... a recent study that came out in the journal Environmental ... plastics on human beings. ,Bisphenol-A (BPA) is a ... grade materials for making air tight containers, drinking water bottles, ... of Medicine did the study to find out about the ...
... that spreads through mosquito bites, among other things, did not ... of Nature Medicine scientists have shown a successful treatment on ... developed an antibody that can successfully fight the virus. The ... naturally against this virus and in turn never get affected ...
... study made by researchers of UK, scientists have found that ... the blood of the passengers. ,The study was done ... today, do have any effect on the health of the ... peripheral oxygen saturation and pulse rate of 84 passengers, aged ...
... cure people suffering from hay fever by teaching them self-hypnosis.//,The ... curing allergic reactions. 79 patients of an average age of ... or pollen were taken in the study. All these people ... years. Random parallel group was used as control for the ...
... to be a risk factor for multiple sclerosis. New ... more in people suffering from multiple sclerosis. ,In ... of medicine, researchers had been able to associate habitual ... sclerosis. In a study comprising of 201 cases of ...
... addiction is a problem because the addicts find it hard ... this type of behavior may be that drugs affect the ... towards other rewards of life, like eating and fulfilling of ... treat drug addiction may be a surgical procedure by which ...
Cached Medicine News:
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. (OTC ... U.S. provisional patent application concerning composition of matter, biological ... targeted tumor cell death.  This patent ... double stranded RNA molecules (VSRNAs) which interfere with the ...
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ...
(Date:1/15/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") ... its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for ... Solta Medical, Inc. (NASDAQ: SLTM ) ("Solta") ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Belgium, December 12, 2011 The peer ... of a clinical trial demonstrating the sedative action of the ... whose abstract is available from the US National Libretry of ... http://www.ncbi.nlm.nih.gov/pubmed/22035386 The results show, ...
... FRANCISCO, Calif., Dec. 10, 2011  Onyx Pharmaceuticals, Inc. (Nasdaq: ... poster presentations of single-agent carfilzomib, a next generation proteasome ... at the 53rd American Society of Hematology (ASH) Annual ... expanded data set supports our belief in the potential ...
Cached Medicine Technology:Insomnia: A No-Drug Solution? 2Onyx Pharmaceuticals Provides Update on Carfilzomib at 53rd American Society of Hematology Annual Meeting 2Onyx Pharmaceuticals Provides Update on Carfilzomib at 53rd American Society of Hematology Annual Meeting 3Onyx Pharmaceuticals Provides Update on Carfilzomib at 53rd American Society of Hematology Annual Meeting 4Onyx Pharmaceuticals Provides Update on Carfilzomib at 53rd American Society of Hematology Annual Meeting 5Onyx Pharmaceuticals Provides Update on Carfilzomib at 53rd American Society of Hematology Annual Meeting 6
Cold light source triple outlet....
With the LX300, you don't have to compromise the quality of your lighting system to meet your budget needs. You get the best and whitest light possible from an affordable 300 Watt light source....
The Carl Zeiss Head-worn Loupes L and LC are the ideal solution if a low magnification suffices for your work and you want to keep your hands free to perform the task at hand....
Head-worn Loupe KF Titanium the teleloupe system is mounted on a special frame with straight temples and an elastic headband....
Medicine Products: